AURORAX-087A (AUR87A) is a planned prospective multi-center observational clinical study to validate the clinical performance of Elypta’s platform in the early detection of recurrence after surgery in patients with high or intermediate risk clear cell renal cell carcinoma. Early detection of recurrence is crucial to improve the chances of survival of patients.
Open for recruitment starting 2020
Sites open in the European Union and United States
Endorsed by European Association of Urology (EAU) Guidelines Panel for Renal Cell Carcinoma Chairman and Vice-Chairman
Endorsed by the International Kidney Cancer Coalition
If you are interested in the progress of AURORAX trials, follow us on LinkedIn!
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 849251